Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for MRD-positive or relapsed/refractory adult Ph+ acute lymphoblastic leukemia
2020-003912-28Phase 2Active
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by GIMEMA. Primary endpoint: Rate of MRD negativity or MRD reduction at 3 months. Started Jun 2021; status: active.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2020-003912-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003912-28.